Published in Eur Urol on November 24, 2011
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ (2014) 2.61
Prostate cancer screening and the management of clinically localized disease. BMJ (2013) 2.45
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol (2015) 2.20
Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. BJU Int (2013) 1.41
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr (2012) 1.11
Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. Rev Urol (2015) 0.91
Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma. Neuro Oncol (2013) 0.84
The benefits of risk assessment tools for prostate cancer. Eur Urol (2011) 0.82
Prostate-specific antigen screening in prostate cancer: perspectives on the evidence. J Natl Cancer Inst (2014) 0.82
Prognostic significance of multiple kallikreins in high-grade astrocytoma. BMC Cancer (2015) 0.80
How should prostate specific antigen be interpreted? Turk J Urol (2013) 0.77
Coupling of prostate and thyroid cancer diagnoses in the United States. Ann Surg Oncol (2014) 0.77
Ethnicity and prostate cancer: the way to solve the screening problem? BMC Med (2015) 0.76
Detection of High-Grade Prostate Cancer among PLCO Participants Using a Prespecified Four Kallikrein Marker Panel. J Urol (2016) 0.76
Association between tumor-associated macrophages and microvessel density on prostate cancer progression. Prostate Int (2015) 0.76
A cluster-randomised, parallel group, controlled intervention study of genetic prostate cancer risk assessment and use of PSA tests in general practice--the ProCaRis study: study protocol. BMJ Open (2013) 0.75
Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA. Oncotarget (2017) 0.75
Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa). EJIFCC (2014) 0.75
A personalized automated messaging system to improve adherence to prostate cancer screening: research protocol. JMIR Res Protoc (2012) 0.75
Update of randomized trials for prostate cancer screening. Rev Urol (2013) 0.75
Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style. J Health Psychol (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making (2006) 11.83
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol (2010) 7.20
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med (1991) 6.94
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med (1987) 6.41
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res (1999) 4.67
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol (2008) 3.83
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo (1995) 3.25
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev (2008) 3.05
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol (2001) 2.87
Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet (1994) 2.83
Balancing the harms and benefits of early detection of prostate cancer. Cancer (2010) 2.71
Human prostate cancer risk factors. Cancer (2004) 2.70
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol (2010) 2.55
Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol (2011) 2.53
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev (2001) 2.47
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet (2008) 2.45
APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem (2006) 2.39
The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol (2008) 2.39
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology (2001) 2.38
Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol (2010) 2.35
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol (2006) 2.24
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21
Comorbidity and competing risks for mortality in men with prostate cancer. Cancer (2011) 2.17
Assessing individual risk for prostate cancer. J Clin Oncol (2007) 2.13
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology (2006) 2.05
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol (2009) 2.02
A systematic review and meta-analysis of familial prostate cancer risk. BJU Int (2003) 2.01
Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol (2011) 1.83
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol (2004) 1.82
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol (2009) 1.81
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer (2007) 1.70
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol (2009) 1.68
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer (2009) 1.59
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol (2011) 1.58
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med (2005) 1.57
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology (2006) 1.51
The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients. J Urol (2010) 1.50
Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer (2003) 1.39
Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol (2010) 1.37
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila) (2010) 1.35
Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol (2004) 1.34
Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control (2009) 1.33
Characteristics of prostate cancer detected by digital rectal examination only. Urology (2007) 1.31
Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol (2011) 1.29
A graphical device to represent the outcomes of a logistic regression analysis. Prostate (2008) 1.25
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology (2004) 1.25
Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer (2003) 1.18
Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol (2010) 1.18
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int (2008) 1.17
Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology (2005) 1.16
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology (1999) 1.16
Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res (1992) 1.15
A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev (2010) 1.12
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol (2008) 1.11
Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer (2007) 1.09
Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer (2007) 1.09
Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology (1995) 1.08
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology (1999) 1.00
Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol (2011) 0.99
PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology (2008) 0.99
Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. Prostate (2011) 0.98
Populations at high risk for prostate cancer. Urol Clin North Am (2003) 0.98
Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction. BJU Int (2010) 0.98
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int (2011) 0.98
Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis (2011) 0.97
Role of family history and ethnicity on the mode and age of prostate cancer presentation. Prostate (2002) 0.96
Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Urology (2009) 0.95
Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol (2008) 0.93
The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control (2011) 0.93
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol (2007) 6.23
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst (2009) 6.07
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ (2014) 4.75
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol (2008) 4.72
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics. N Engl J Med (2015) 4.58
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15
Empirical study of data sharing by authors publishing in PLoS journals. PLoS One (2009) 4.09
Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2012) 4.07
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int (2008) 3.94
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med (2010) 3.85
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol (2010) 3.79
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 3.59
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ (2010) 3.38
Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol (2012) 3.34
Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst (2007) 3.26
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol (2012) 3.07
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer (2002) 3.05
Low annual caseloads of United States surgeons conducting radical prostatectomy. J Urol (2009) 3.04
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology (2002) 2.87
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol (2006) 2.71
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med (2015) 2.71
Balancing the harms and benefits of early detection of prostate cancer. Cancer (2010) 2.71
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. Eur Urol (2008) 2.66
Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol (2008) 2.65
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol (2008) 2.57
Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol (2010) 2.55
Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol (2008) 2.55
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. Trials (2010) 2.54
Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst (2002) 2.54
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol (2006) 2.50
Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst (2006) 2.48
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol (2013) 2.43
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res (2010) 2.39
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol (2010) 2.33
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer (2005) 2.25
Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol (2006) 2.24
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev (2009) 2.20
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med (2003) 2.16
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol (2008) 2.16